<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297606</url>
  </required_header>
  <id_info>
    <org_study_id>PM1</org_study_id>
    <secondary_id>ESR-17-12831</secondary_id>
    <secondary_id>CA209-9DL</secondary_id>
    <secondary_id>ML39800</secondary_id>
    <secondary_id>WI233446</secondary_id>
    <nct_id>NCT03297606</nct_id>
  </id_info>
  <brief_title>Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)</brief_title>
  <acronym>CAPTUR</acronym>
  <official_title>Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer drugs which target the effects of abnormal gene changes are called 'targeted&#xD;
      therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are&#xD;
      currently available. The purpose of this study is to find out what are the effects on a&#xD;
      patient and their cancer when they are given a targeted therapy drug that is specific to an&#xD;
      abnormal gene change in their cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent advances in laboratory technology have enabled the identification of changes in the&#xD;
      genetic makeup of tumors that might be responsible for their malignant behavior such as&#xD;
      uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be&#xD;
      cancer medicines that can specifically act on the tumour's genetic abnormality. Several&#xD;
      cancer centers and programs have initiated this type of molecular profiling across Canada,&#xD;
      with the goal to identify 'druggable' changes in tumors to find matching therapy for&#xD;
      patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian&#xD;
      Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of&#xD;
      commercially available targeted agents in patients who have undergone tumor profiling and&#xD;
      have 'druggable' changes identified in their cancers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate defined as the number of patients with complete response or partial response</measure>
    <time_frame>4 years</time_frame>
    <description>over the total number of patients in a given cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events grade &gt;3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug</measure>
    <time_frame>4 years</time_frame>
    <description>measured by CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival by disease-appropriate objective criteria</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGFR1, VEGFR2, VEGFR3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCR-ABL, SRC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALK, ROS1, MET</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KIT, PDGFRA, PDGFRB, ABL1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high mutation burden, POLE, POLD1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRCA1, BRCA2, mutations in HRD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CDKN2A, CDK4, CCND1, SMARCA4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ERBB2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BRAFV600</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTCH1, SMO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>300mg taken twice daily</description>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100mg administered orally once daily</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab plus Ipilimumab</intervention_name>
    <description>Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.&#xD;
Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.</description>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>5mg orally twice daily</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosutinib</intervention_name>
    <description>500mg orally once daily</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>250mg orally twice daily</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days</description>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off</description>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25mg infused over a 30-60 minute period once a week</description>
    <arm_group_label>Group 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>150mg orally, once daily</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab plus Pertuzumab</intervention_name>
    <description>Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.&#xD;
Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.</description>
    <arm_group_label>Group 11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib plus Cobimetinib</intervention_name>
    <description>Vemurafenib = 960 mg orally every 12 hours.&#xD;
Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest</description>
    <arm_group_label>Group 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vismodegib</intervention_name>
    <description>150mg taken orally, once daily</description>
    <arm_group_label>Group 13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (screening step - non-drug specific)&#xD;
&#xD;
          -  Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid&#xD;
             tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin&#xD;
             lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known&#xD;
             to prolong life, or who has refused such treatment.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Patients must have normal organ function as follows:&#xD;
&#xD;
               -  Absolute neutrophil count: ≥ 1.5 x 10^9/L for solid tumours; ≥ 1.0 x 10^9/L for&#xD;
                  neurologic malignancies&#xD;
&#xD;
               -  Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma&#xD;
                  or lymphoma).&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x UNL.&#xD;
&#xD;
               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless&#xD;
                  liver metastases are present in which case they must be &lt; 5 x ULN;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥&#xD;
                  50mg/min/1.73µ^2&#xD;
&#xD;
          -  Patients must have measurable disease&#xD;
&#xD;
          -  Results must be available from tumour genomic or protein expression testing (if used&#xD;
             to identify genetic variants), from one of the initiatives / groups listed in protocol&#xD;
             Appendix VII. The test may have been performed on the primary tumour or a metastatic&#xD;
             deposit (including bone marrow), or blood, in a diagnostic or research laboratory and&#xD;
             must reveal a potentially actionable variant.&#xD;
&#xD;
          -  Patient consent (Main Study Consent for the screening step) must be appropriately&#xD;
             obtained in accordance with applicable local and regulatory requirements. Each patient&#xD;
             must sign a consent form prior to the screening step to document their willingness to&#xD;
             participate&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up. Patients registered on this&#xD;
             trial must be treated and followed at the participating centre or a CCTG IND site.&#xD;
             This implies there must be reasonable geographical limits (for example: 1 ½ hour's&#xD;
             driving distance) placed on patients being considered for this trial.&#xD;
&#xD;
          -  Women/men of childbearing potential must have agreed to use a highly effective&#xD;
             contraceptive method.&#xD;
&#xD;
        Exclusion Criteria: (screening step - non-drug specific)&#xD;
&#xD;
          -  Patients with prior or concurrent malignancy whose natural history or treatment has&#xD;
             the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen.&#xD;
&#xD;
          -  Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy or&#xD;
             asymptomatic, corrected biochemical toxicities (e.g. hypothyroidism corrected by&#xD;
             thyroid replacement), related to prior anti-tumour treatment. Patients with ongoing&#xD;
             peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.&#xD;
&#xD;
          -  Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic,&#xD;
             radiation, or hormonal other than for replacement) except for medications that are&#xD;
             prescribed for supportive care but may potentially have an anti-cancer effect (e.g.&#xD;
             megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate&#xD;
             cancer. These medications must have been started ≥ one month prior to enrollment on&#xD;
             this study. Patients may be on warfarin, low molecular weight heparin or direct factor&#xD;
             Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility&#xD;
             criteria.&#xD;
&#xD;
          -  Patients with known active progressive brain metastases. Patients with previously&#xD;
             treated brain metastases are eligible, provided that the patient has not experienced a&#xD;
             seizure or had a clinically significant change in neurological status within one month&#xD;
             prior to screening. All patients with previously treated brain metastases must be&#xD;
             stable (clinically and radiologically) for at least one month after completion of&#xD;
             treatment and either off steroid treatment or only taking physiological doses of&#xD;
             steroids prior to the screening step.&#xD;
&#xD;
          -  Patients with clinically significant pre-existing cardiac conditions, including&#xD;
             uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or&#xD;
             symptomatic congestive heart failure.&#xD;
&#xD;
          -  Patients with known left ventricular ejection fraction (LVEF) &lt; 40%.&#xD;
&#xD;
          -  Patients with stroke (including TIA) or acute myocardial infarction within three&#xD;
             months prior to the screening step.&#xD;
&#xD;
          -  Patients with acute gastrointestinal bleeding within one month prior to the screening&#xD;
             step.&#xD;
&#xD;
          -  Patients with any other clinically significant medical condition which, in the opinion&#xD;
             of the treating physician, makes it undesirable for the patient to participate in the&#xD;
             study or which could jeopardize compliance with study requirements including, but not&#xD;
             limited to: ongoing or active infection, significant uncontrolled hypertension, or&#xD;
             severe psychiatric illness/social situations.&#xD;
&#xD;
          -  Lactating and nursing women&#xD;
&#xD;
          -  Patients who do not meet drug-specific eligibility requirements for the drug selected&#xD;
             by the treating physician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian Siu</last_name>
    <role>Study Chair</role>
    <affiliation>Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel J Renouf</last_name>
    <role>Study Chair</role>
    <affiliation>BCCA - Vancouver Cancer Centre, Vancouver BC, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Dancey</last_name>
    <phone>613-533-6430</phone>
    <email>jdancey@ctg.queensu.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quincy Chu</last_name>
      <phone>780 432-8248</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BCCA - Cancer Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Kristina Taylor</last_name>
      <phone>250 712-3996</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel John Renouf</last_name>
      <phone>604 877-6000</phone>
      <phone_ext>672357</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Vera-Badillo</last_name>
      <phone>613 533-6430</phone>
      <phone_ext>78769</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Welch</last_name>
      <phone>519 685-8640</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Hilton</last_name>
      <phone>613 737-7700</phone>
      <phone_ext>75086</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillian Siu</last_name>
      <phone>416 946-2911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristiano Ferrario</last_name>
      <phone>514 398-8307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Hagel</last_name>
      <phone>306 766-2691</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil K. Yadav</last_name>
      <phone>306 655-2710</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 27, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

